3 September 2019
Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority by National and International bodies. There are relatively few agents in developmental pipelines and a paucity of identified microbiological targets that can be exploited for drug development.
Co-sponsored by the American Society for Microbiology (ASM) and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), this multidisciplinary meeting will address the challenges, opportunities and current requirements for antimicrobial drug development for AMR.
Dates: Sep 3, 2019 – Sep 6, 2019
Join us to explore the challenges, opportunities and current requirements for antimicrobial drug development for Antimicrobial Resistance.